Compare Abeona Therapeutics Inc (ABEO) vs iShares iBoxx $ Inv Grade Corporate Bond ETF (LQD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs iShares iBoxx $ Inv Grade Corporate Bond ETF — how do they compare? Abeona Therapeutics Inc trades at $6.19 (market cap $425.47M), while iShares iBoxx $ Inv Grade Corporate Bond ETF trades at $106.43. The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, iShares iBoxx $ Inv Grade Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| ABEO | LQD | |
|---|---|---|
Market Cap | $425.47M | — |
Sector | Health | — |
52-Week High | $7.46 | $112.91 |
52-Week Low | $4.17 | $105.96 |
Enterprise Value | $280.37M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.46, up 0.13% with strong technical momentum as moving averages signal bullish sentiment. The company shows exceptional profitability with 454.86% net income margin and 70.99% ROE, though revenue remains modest at $5.82M. Recent positive developments include CMS granting NTAP status for ZEVASKYN and expanding treatment centers, while consistently beating earnings expectations.
Outlook remains positive with analyst consensus at 66.7% buy ratings, but risks include shareholder investigation and high RSI levels suggesting overbought conditions. The stock's valuation appears reasonable with P/E of 7.78, though negative operating cash flow requires monitoring as the company scales commercialization efforts.
LQD trades at $106.12 with minimal daily movement (+0.15%). Technical indicators show a bearish bias with moving averages signaling sell pressure, though oscillators remain neutral. The ETF maintains consistent dividend distributions, with recent payouts ranging from $0.38 to $0.46 per share. Market focus remains on inflation data and Federal Reserve policy amid ongoing Middle East tensions affecting bond yields.
Investment-grade corporate bond ETFs face headwinds from rising Treasury yields and inflation concerns. LQD's stability in dividend payments provides income appeal, but technical weakness suggests cautious near-term positioning. Key risks include interest rate sensitivity and geopolitical volatility impacting fixed income markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About iShares iBoxx $ Inv Grade Corporate Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in fixed income securities of the types included in the underlying index that the advisor believes will help the fund track the underlying index. The underlying index is designed to provide a broad representation of the US dollar-denominated liquid investment-grade corporate bond market.
Read more on LQD →
